source
- Evommune gives up hope for MRGPRX2 antagonist to treat itch after latest phase 2 failEvommune’s MRGPRX2 antagonist has flunked another phase 2 trial, wiping out the biotech’s last hopes of developing the therapy for any itch-related conditions.
- ARPA-H commits $62.7 million to develop FDA-authorized AI for heart-failure treatmentARPA-H announced a $62.7 million investment to create artificial-intelligence systems that can assist in treating heart failure. The program, called ADVOCATE, seeks to develop partially autonomous…